NasdaqGS - Delayed Quote • USD
Ironwood Pharmaceuticals, Inc. (IRWD)
At close: 4:00 PM EDT
After hours: 5:31 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 5 | 5 | 6 | 5 |
Avg. Estimate | 0.2 | 0.2 | 0.68 | 0.81 |
Low Estimate | 0.1 | 0.12 | 0.51 | 0.66 |
High Estimate | 0.48 | 0.37 | 0.87 | 0.93 |
Year Ago EPS | 0.25 | -6.71 | -6.45 | 0.68 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 5 | 5 | 6 | 5 |
Avg. Estimate | 106.3M | 112.16M | 448.27M | 488.2M |
Low Estimate | 102.1M | 109.12M | 436.5M | 461.1M |
High Estimate | 111.7M | 114.5M | 453.3M | 514.8M |
Year Ago Sales | 100.41M | 107.38M | 442.74M | 448.27M |
Sales Growth (year/est) | 5.90% | 4.40% | 1.30% | 8.90% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | 0.24 | 0.25 | 0.16 | 0.21 |
EPS Actual | 0.25 | -6.71 | 0.09 | -0.01 |
Difference | 0.01 | -6.96 | -0.07 | -0.22 |
Surprise % | 4.20% | -2,784.00% | -43.80% | -104.80% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.2 | 0.2 | 0.68 | 0.81 |
7 Days Ago | 0.2 | 0.2 | 0.68 | 0.81 |
30 Days Ago | 0.2 | 0.2 | 0.68 | 0.84 |
60 Days Ago | 0.17 | 0.19 | 0.75 | 0.88 |
90 Days Ago | 0.15 | 0.18 | 0.79 | 0.88 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | IRWD | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -20.00% | -- | -- | 2.60% |
Next Qtr. | 103.00% | -- | -- | 13.40% |
Current Year | 110.50% | -- | -- | 5.20% |
Next Year | 19.10% | -- | -- | 13.30% |
Next 5 Years (per annum) | 72.58% | -- | -- | 11.11% |
Past 5 Years (per annum) | 6.41% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | Wells Fargo: Overweight to Overweight | 3/1/2024 |
Maintains | Piper Sandler: Overweight to Overweight | 2/16/2024 |
Initiated | Craig-Hallum: Buy | 1/17/2024 |
Initiated | Wells Fargo: Overweight | 12/14/2023 |
Initiated | JMP Securities: Market Outperform | 9/28/2023 |
Maintains | Piper Sandler: Overweight to Overweight | 5/23/2023 |
Related Tickers
SUPN Supernus Pharmaceuticals, Inc.
29.31
-3.14%
ALKS Alkermes plc
24.44
-0.85%
DCPH Deciphera Pharmaceuticals, Inc.
14.18
-3.01%
PCRX Pacira BioSciences, Inc.
25.50
-1.54%
COLL Collegium Pharmaceutical, Inc.
35.84
+1.01%
NBIX Neurocrine Biosciences, Inc.
137.76
-0.87%
EGRX Eagle Pharmaceuticals, Inc.
4.2400
-6.81%
PETQ PetIQ, Inc.
16.32
-1.27%
ELAN Elanco Animal Health Incorporated
13.04
-2.03%
HCM HUTCHMED (China) Limited
18.99
+3.15%